Resumen
The management of fibromyalgia syndrome (FMS) has traditionally been multimodal and multidisciplinary, including education, physical modalities, and medication. In this article, an acronym is offered to help the clinician remember the important components of management. An improved understanding of the pathogenesis of FMS has allowed substantial refinements in its treatment. This is particularly true for medications that target specific symptom domains, allowing individualization of therapy. Since all FMS patients experience pain, there has been emphasis on that domain although medications are now available to address two or more domains with monotherapy. In addition, a logical basis is provided to help the clinician design strategic polypharmacy.
Idioma original | English (US) |
---|---|
Páginas (desde-hasta) | 27-33 |
Número de páginas | 7 |
Publicación | CNS spectrums |
Volumen | 13 |
N.º | 3 SUPPL. 5 |
DOI | |
Estado | Published - mar 2008 |
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health